A novel closed-loop feedback neuromodulation system for improving slow wave sleep in alzheimer's disease patients
Active Project Grant Awarded Last action
- Award ID
- R43AG084379
- Recipient
-
Synaptic Health LLC UEI Z8EJTFJKU3F8
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,498,158
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 73% complete
- Originally
- Place of performance
- Minnesota, USA
Award details come from USAspending.gov.
Description
- Abstract
- Abstract sleep disturbances are a common facet of alzheimer's disease (ad) affecting 20-40% of patients in the mild to moderate stage of the illness. There is strong evidence that poor sleep accelerates the progress of ad through the failure to clear brian toxins during sleep. Research has shown that promoting healthy sleep, specifically slow wave sleep (SWS), reversed the accelerating impacts of disrupted sleep in ad patients and reduced their annual increases in ad biomarkers, reduced cognitive decline, stabilized depressive symptoms, and improved psychopathological behavior. There is increasing evidence that promoting sleep, specifically healthy sleep architecture, reduces the risk of poor sleep accelerating ad. However, there are currently no approved therapies that are specifically designed to promote sleep and healthy sleep architecture in ad patients and patients at high risk for ad. Thus, there is a significant unmet clinical need to develop a sleep promoting device that is well tolerated by pre-ad and early-stage ad patients. Our innovation is a device that promotes sleep onset, sleep duration, and the ideal sleep stage architecture including SWS, to prevent the disease accelerating impacts of disrupted sleep on ad patients. The goal of this phase I project is to create a testable prototype that can sense sleep architecture and provide peripheral neuromodulation stimulation to individuals over the age of 65, a group with an elevated risk of ad. Successful completion of this phase I effort will position US to demonstrate in clinical studies that our device improves SWS in early-stage ad patients and reduces ad biomarkers. Our final commercialized device will be a comfortable low-profile medical device that promotes healthy sleep in high-risk and early-stage ad patients and reverses the accelerating effects of disrupted sleep for millions of ad patients.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $499,386 | |
| Amendment | $499,386 | |
| Original award | $499,386 |
Show all 13
Quick answers
Who received award R43AG084379?
R43AG084379 was awarded to Synaptic Health LLC by National Institute on Aging (National Institutes of Health) on September 25, 2024.
How much is award R43AG084379 worth?
$1,498,158 has been obligated on R43AG084379.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award